Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Relapsed/Refractory Germ Cell Cancer
NCT01242631Phase 2Completed
- Sponsor
- Hannover Medical School
- Start
- Nov 2010
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in Germ cell cancer (GCT), sponsored by Hannover Medical School. Primary endpoint: Progression-free rate at 12 weeks. Started Nov 2010; status: completed.
02
Drugs
everolimus
03
Conditions
Germ cell cancer (GCT)
Beyond the preview
Go deeper on NCT01242631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01242631.